Pharmacogenetics of osteoporosis

References

• Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet359, 1929–1936 (2002).
   PubMed Web of Science ®Google Scholar
• Melton LJ 3rd, Atkinson EJ, O’Connor MK, O’Fallon WM, Riggs BL. Bone density and fracture risk in men. J. Bone Miner. Res.13, 1915–1923 (1998).
   PubMed Web of Science ®Google Scholar
• Melton LJ 3rd. How many women have osteoporosis now? J. Bone Miner. Res.10, 175–177 (1995).
   PubMed Web of Science ®Google Scholar
• Ralston SH. Genetics of osteoporosis. Ann. NY Acad. Sci.1192, 181–189 (2010).
   Web of Science ®Google Scholar
• Shin J, Kayser SR, Langaee TY. Pharmacogenetics: from discovery to patient care. Am. J. Health Syst. Pharm.66(7), 625–637 (2009).
   Google Scholar
• Johnson JA, Evans WE. Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. Trends Mol. Med.8(6), 300–305 (2002).
   Google Scholar
• Nguyen TV, Eisman JA. Pharmacogenomics of osteoporosis: opportunities and challenges. J. Musculoskelet. Neuronal Interact.6, 62–72 (2006).
   PubMedGoogle Scholar
• Yahata T, Quan J, Tamura N, Nagata H, Kurabayashi T, Tanaka K. Association between single nucleotide polymorphisms of estrogen receptor α gene and efficacy of HRT on bone mineral density in post-menopausal Japanese women. Hum. Reprod.20, 1860–1866 (2005).
   PubMedGoogle Scholar
• Rapuri PB, Gallagher JC, Knezetic JA, Haynatzka V. Estrogen receptor α gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas53(4), 371–379 (2006).
   Google Scholar
• Ongphiphadhanakul B, Chanprasertyothin S, Payatikul P et al. Oestrogen-receptor- α gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clin. Endocrinol. (Oxf.)52, 581–585 (2000).
   PubMed Web of Science ®Google Scholar
• Salmén T, Heikkinen AM, Mahonen A et al. The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor α genotype in early postmenopausal women. J. Bone Miner. Res.15, 2479–2486 (2000).
   PubMed Web of Science ®Google Scholar
• Kurabayashi T, Tomita M, Matsushita H et al. Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am. J. Obstet. Gynecol.180, 1115–1120 (1999).
   PubMed Web of Science ®Google Scholar
• Kurabayashi T, Matsushita H, Tomita M et al. Association of vitamin D and estrogen receptor gene polymorphism with the effects of longterm hormone replacement therapy on bone mineral density. J. Bone Miner. Metab.22, 241–247 (2004).
   Google Scholar
• Giguère Y, Dodin S, Blanchet C, Morgan K, Rousseau F. The association between heel ultrasound and hormone replacement therapy is modulated by a two-locus vitamin D and estrogen receptor genotype. J. Bone Miner. Res.15(6), 1076–1084 (2000).
   PubMed Web of Science ®Google Scholar
• Simsek M, Cetin Z, Bilgen T, Taskin O, Luleci G, Keser I. Effects of hormone replacement therapy on bone mineral density in Turkish patients with or without COL1A1 Sp1 binding site polymorphism. J. Obstet. Gynaecol. Res.34(1), 73–77 (2008).
   Google Scholar
• Rosen CJ, Kessenich CR. The pathophysiology and treatment of postmenopausal osteoporosis. An evidence-based approach to estrogen replacement therapy. Endocrinol. Metab. Clin. North Am.26, 295–311 (1997).
   Google Scholar
• Palomba S, Numis FG, Mossetti G et al. Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum. Reprod.18, 192–198 (2003).
   Google Scholar
• Heilberg IP, Hernandez E, Alonzo E et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Ren. Fail.27(2), 155–161 (2005).
   PubMed Web of Science ®Google Scholar
• Marc J, Prezelj J, Komel R, Kocijancic A. VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporos. Int.10, 303–306 (1999).
   PubMed Web of Science ®Google Scholar
• Palomba S, Orio F Jr, Russo T et al. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos. Int.16, 943–952 (2005).
   PubMed Web of Science ®Google Scholar
• Arko B, Prezelj J, Komel R, Kocijancic A, Marc J. No major effect of estrogen receptor β gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis. J. Steroid Biochem. Mol. Biol.81, 147–152 (2002).
   PubMed Web of Science ®Google Scholar
• Qureshi AM, Herd RJ, Blake GM, Fogelman I, Ralston SH. Colia1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcif. Tissue Int.70, 158–163 (2002).
   PubMed Web of Science ®Google Scholar
• Marini F, Falchetti A, Silvestri S et al. Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. Curr. Med. Res. Opin.24(9), 2609–2615 (2008).
   PubMed Web of Science ®Google Scholar
• Choi HJ, Choi JY, Cho SW et al. Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women. Yonsei Med. J.51(2), 231–238 (2010).
   PubMed Web of Science ®Google Scholar
• Kruk M, Ralston SH, Albagha OM. LRP5 polymorphisms and response to risedronate treatment in osteoporotic men. Calcif. Tissue Int.84(3), 171–179 (2009).
   PubMed Web of Science ®Google Scholar
• Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr. Opin. Rheumatol.17, 462–466 (2005).
   PubMed Web of Science ®Google Scholar
• Farrugia MC, Summerlin DJ, Krowiak E et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope116, 115–120 (2006).
   PubMed Web of Science ®Google Scholar
• Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg.63, 1567–1575 (2005).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N. Engl. J. Med.356, 1895–1896 (2007).
   PubMed Web of Science ®Google Scholar